Single-Domain Antibodies Targeting CTLA-4
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for CTLA-4-related diseases, such as cancer, face challenges in effectively targeting CTLA-4 with sufficient specificity and affinity, limiting their therapeutic efficacy.
Innovation Solution
Development of single-domain antibodies (sdAbs) specifically recognizing CTLA-4, comprising defined CDR1, CDR2, and CDR3 sequences, which can be used alone or fused with full-length antibodies or other antigen binding fragments to create multispecific binding proteins, enhancing antigen binding and therapeutic targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional 4-chain antibodies are used to target CTLA-4, then they provide sufficient antigen binding, but they have limitations in specificity and affinity that limit therapeutic efficacy
Solution Approach 1:
The patent segments the conventional 4-chain antibody structure into single-domain antibody units (VHH, VL, or VH-VL) that can independently bind CTLA-4. This segmentation allows for optimized binding affinity and specificity while maintaining therapeutic efficacy, directly resolving the contradiction between reliability and measurement precision.
Solution Approach 2:
The patent changes the structural parameters of the antibody by using single-domain formats with defined CDR1, CDR2, and CDR3 sequences. This parameter change enables enhanced binding characteristics to CTLA-4, improving both specificity and affinity while maintaining therapeutic reliability.
2Measurement precision
If single-domain antibodies are designed with specific CDR sequences, then affinity and specificity for CTLA-4 are enhanced, but the complexity of antibody design and characterization increases
Solution Approach 1:
The patent creates universal single-domain antibody templates with optimized CDR sequences that can target CTLA-4 effectively. These standardized designs reduce the complexity of developing new antibody variants while maintaining high affinity and specificity, resolving the contradiction between measurement precision and device complexity.
Solution Approach 2:
By defining specific CDR sequence parameters (CDR1, CDR2, CDR3) for the single-domain antibodies, the patent establishes optimized binding characteristics. This parameter optimization achieves high affinity and specificity while providing a systematic design framework that manages complexity.
3Weight of moving object
If single-domain antibodies are used instead of conventional antibodies, then the molecular weight is reduced and tissue penetration is improved, but the stability and half-life may be compromised
Solution Approach 1:
The patent employs composite antibody structures where single-domain units are combined with Fc regions or other stabilizing elements. This composite approach reduces molecular weight for better tissue penetration while the Fc portion provides extended half-life, resolving the contradiction between weight and duration of action.
Solution Approach 2:
The patent segments the antibody into separate functional domains (single-domain variable regions combined with Fc regions). This segmentation allows the light single-domain portion to penetrate tissues effectively while the heavier Fc portion provides stability and extended circulation half-life.
Data Source
AI summary
The present application provides constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Also provided are methods of making and using these constructs.